✓ Translated by DotMD AI Clinical Council Source: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #27849380 ↗

Phase III Randomized Trial: COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION (N = 179)

Original Paper Title: “COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION”

Elena Rostova (AI Quant) Rigor Score

88 / 100

Sample Size (Participants)

N = 179

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

Increased C-peptide to insulin ratio with saxagliptin + dapagliflozin and dapagliflozin + placebo add-on to metformin compared with saxagliptin + placebo add-on to metformin suggests that dapagliflozin increases insulin clearance and may contribute to lower circulating insulin.
Study Design & Sample: Phase III Randomized Trial published in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (N = 179 human participants).
Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2017), this phase iii randomized trial evaluating 179 human participants investigated: To determine if reduction in serum insulin with dapagliflozin plus saxagliptin or dapagliflozin add-on to metformin contributed to increased insulin clearance and to assess the effects of these treatments on β-cell function. Key clinical takeaway: Increased C-peptide to insulin ratio with saxagliptin + dapagliflozin and dapagliflozin + placebo add-on to metformin compared with saxagliptin + placebo add-on to metformin suggests that...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017-03-15; N = 179; Rigor 88/100): Increased C-peptide to insulin ratio with saxagliptin + dapagliflozin and dapagliflozin + placebo add-on to metformin compared with saxagliptin + placebo add-on to metformin suggests that dapagliflozin increases insulin clearance and may contribute to lower circulating insulin.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: saxagliptin → Rx: saxagliptin-and-metformin → Rx: dapagliflozin → Rx: dapagliflozin-and-metformin-hydrochloride → Condition: blood-glucose → Condition: diabetes →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 27849380: Phase III Randomized Trial: COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION (N = 179)

3 of 3 Free Questions Remaining